Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Spectrum Pharmaceuticals, Inc.    SPPI   US84763A1088

News SummaryMost relevantAll newsSector news 

Spectrum Pharmaceuticals, Inc. : Hagens Berman Notifies Spectrum Pharmaceuticals Investors of Pending Class-Action Lawsuit and May 13, 2013, Lead Plaintiff Deadline

03/22/2013 | 08:35am US/Eastern

Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, is investigating Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) ("Spectrum" or "The Company") following the filing of a class-action lawsuit on behalf of investors. The firm encourages those who have suffered losses to contact Hagens Berman Partner Reed Kathrein, who is leading the Firm's investigation, by emailing

A class-action lawsuit filed in U.S. District Court identifies a class of Spectrum investors who purchased stock in the company between August 8, 2012, and March 12, 2013, inclusive (the "class period"). Those who suffered significant losses and wish to move to be a lead plaintiff may also contact the firm by calling (510) 725-3000.

Investors who wish to serve as lead plaintiff in the case must move the court no later than May 13, 2013. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

On March 12, 2013, Spectrum disclosed to investors that it would significantly lower its 2013 revenue guidance on concerns that sales of its drug FUSILEV would be lower than expected. Following the disclosure, Spectrum's stock price fell dramatically, from a close of $12.43 per share on March 12 to a close of $7.79 per share on March 13. The stock has continued to trade at or around $7.00 since the disclosure.

Hagens Berman's investigation centers around whether Spectrum knew and failed to disclose to investors concerns about the sales of FUSILEV.

"We are concerned that Spectrum knew that generic competition would substantially impact the company's revenues and failed to disclose these concerns to investors," said Mr. Kathrein. "We believe the company's alleged failure to come clean with investors about these issues may have artificially inflated the stock price, resulting in very significant investor losses."

Hagens Berman reminds whistleblowers with inside information that rewards may be available to individuals who report information leading to a successful enforcement action by the Securities and Exchange Commission. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.

More information about this investigation is available at

About Hagens Berman

Hagens Berman Sobol Shapiro LLP is an investor-rights class-action law firm with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the law firm and its successes can be found at The Firm's securities law blog is at

Firmani + Associates
Mark Firmani, 206-443-9357

© Business Wire 2013
React to this article
03/04 SPECTRUM PHARMACEUTICALS : In-Licenses Poziotinib, a Novel pan-HER Inhibitor Wit..
03/04 ONXEO : 2014 Onxeo Review and 2015 Perspectives
02/25 SPECTRUM PHARMACEUTICALS : Patent Issued for Sensitization of Tumor Cells to Rad..
02/25 SPECTRUM PHARMACEUTICALS : Market Updates on Biotech Stocks - Hemispherx Biophar..
02/23 SPECTRUM PHARMACEUTICALS : Nasdaq stocks posting largest percentage decreases
02/23 SPECTRUM PHARMACEUTICALS : Regulation FD Disclosure (form 8-K)
02/21 SPECTRUM PHARMACEUTICALS : Reviews Clinical Data for Captisol-Enabled Melphalan ..
02/21 SPECTRUM PHARMACEUTICALS : Sets Fourth Quarter 2014 Financial Results and Analys..
02/20 SPECTRUM PHARMACEUTICALS : Change in Directors or Principal Officers (form 8-K)
02/20 SPECTRUM PHARMACEUTICALS : to Present Corporate Update at the 2015 RBC Capital M..
Duration : Period :
Spectrum Pharmaceuticals,  Technical Analysis Chart | SPPI | US84763A1088 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes